MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ctro.2026.101142

Медицинская библиотека · Clinical and translational radiation oncology · 2026

Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.

Schäfer Sebastian, Seiler Isabell, Kästner Lena, Meents Johannes, Slavik Marek, Burkon Petr, Loi Mauro, Bonomo Pierluigi, von Wachter Camilla, Balermpas Panagiotis, Schunn Anna Sabrina, Drabke Sophia, Holy Richard, Klischies Kenneth, Wittenstein Olaf, Willner Jochen, Baehr Andrea, Bank Priska, Partl Richard, Mader Thomas, Frerker Bernd, Lohaus Fabian, Ehret Felix, Trommer Maike, Gkika Eleni, Rühle Alexander, Guckenberger Matthias, Moustakis Christos, Brunner Thomas, Blanck Oliver, Heggemann Judit Boda-, Nicolay Nils H, Nägler Franziska

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: The interdisciplinary treatment concept for bone metastases (BoM) of oligometastatic breast cancer includes metastasis-directed radiotherapy. We evaluated oncological outcomes of BoM treated with stereotactic body radiotherapy (SBRT) in a large European cohort.

MATERIAL AND

METHODS

Data of breast cancer patients treated with SBRT for BoM between 2010 and 2024 at 17 European cancer centers were retrospectively collected. Treatment and dose concepts were analyzed regarding their impact on freedom from local recurrence (FFLR), overall survival (OS), progression-free survival (PFS), and safety profile.

RESULTS

With a median follow-up of 29.6 months (interquartile range: 15.0-48.0), 109 patients with 147 BoM were analyzed. SBRT was performed with a prescribed dose of median 35 Gy in median 5 fractions. 1-/3-year FFLR for mean biologically effective dose (BED10) ≥ 50 Gy in the gross tumor volume (GTVmean) was 98.1% (95%-CI: 92.7%-99.5%) and 93.9% (95%-CI: 85.5%-97.5%), respectively. For GTVmean BED10 ≥ 50 Gy, 1-/3-year PFS was 62.1% (95%-CI: 43.6%-76.0%)/26.7% (95%-CI: 11.0%-45.4%) for non-spine BoM and 66.2% (95%-CI: 50.8%-77.8%)/35.8% (95%-CI: 21.3%-50.4%) for spine BoM. In multivariable analysis, systemic therapy (HR [hazard ratio] 0.22; p < 0.001) was associated with improved OS, while higher GTVmean BED10 (HR 0.96; p < 0.001) was associated with improved PFS and spine localization with worse PFS (HR 1.81; p = 0.02). Adverse events were rare, with fracture rates of 2.7%.

CONCLUSION

In this multicenter retrospective cohort analysis, SBRT of BoM from breast cancer was a well-tolerated, effective treatment. Prospective studies are needed to investigate these findings further and determine the role of standardized SBRT concepts in the multidisciplinary management of oligometastatic breast cancer.

Для цитирования: Schäfer Sebastian, Seiler Isabell, Kästner Lena, Meents Johannes, Slavik Marek, Burkon Petr, Loi Mauro, Bonomo Pierluigi, von Wachter Camilla, Balermpas Panagiotis, Schunn Anna Sabrina, Drabke Sophia, Holy Richard, Klischies Kenneth, Wittenstein Olaf, Willner Jochen, Baehr Andrea, Bank Priska, Partl Richard, Mader Thomas, Frerker Bernd, Lohaus Fabian, Ehret Felix, Trommer Maike, Gkika Eleni, Rühle Alexander, Guckenberger Matthias, Moustakis Christos, Brunner Thomas, Blanck Oliver, Heggemann Judit Boda-, Nicolay Nils H, Nägler Franziska. Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.. Clinical and translational radiation oncology. 2026. DOI: 10.1016/j.ctro.2026.101142.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.